Innovent reports cancer drug results in breast, lung, pancreatic tumors

What happened: Innovent Biologics (IVBIY)(IVBXF) reported clinical trial results for two experimental antibody-drug conjugate cancer drugs at the European Society for Medical Oncology's 2026 congress in Madrid. Key numbers: IBI354 plus pertuzumab produced confirmed tumor shrinkage Why it matters: The findings add evidence for Innovent's ADC portfolio, a competitive area of cancer drug development, and Phase 3 trials of IBI354 are already underway in breast and ovarian cancers. Small patient populations and lack of randomized comparison groups limit assessment against established therapies.

Innovent Biologics (IVBIY)(IVBXF) reported clinical trial results for two experimental antibody-drug conjugate cancer drugs at the European Society for Medical Oncology's 2026 congress in Madrid.

The findings add evidence for Innovent's ADC portfolio, a competitive area of cancer drug development, and Phase 3 trials of IBI354 are already underway in breast and ovarian cancers. Small patient populations and lack of randomized comparison groups limit assessment against established therapies.